Understanding how p53 loss in lung cancer affects protein secretion and cancer spread
A pro-metastatic secretory pathway activated by p53 loss in lung cancer
This study is looking at how a missing protein in lung cancer cells helps them grow and spread by releasing more proteins, and it’s testing a new drug that could help slow down this process to improve the lives of lung cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10873872 on NIH RePORTER |
What this research studies
This research investigates how the loss of the p53 protein in lung cancer cells enhances their ability to secrete proteins that support their growth and spread. By studying the Golgi apparatus, which regulates protein transport, the researchers aim to uncover the mechanisms behind this increased secretion. They have identified a drug that can block the formation of a protein complex involved in this process, potentially leading to new therapies that inhibit cancer progression. The goal is to improve the length and quality of life for lung cancer patients by targeting these secretory pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer, particularly those with mutations affecting the p53 protein.
Not a fit: Patients with lung cancer who do not have p53 loss or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow down or prevent the spread of lung cancer.
How similar studies have performed: Other research has shown promising results in targeting secretory pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Kurie, Jonathan M — University of Tx Md Anderson Can Ctr
- Study coordinator: Kurie, Jonathan M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.